Evidence map›Paper›PMID 39810058›Full record

ArticleInternational urology and nephrology2025

Synergy of zinc oxide nanoparticles to losartan attenuates kidney injury induced by unilateral ureteral obstruction through modulation of the TNF-α/IL6 and BAX/BCL2 signaling pathways.

Yomna Khater, Nashwa Barakat, Ahmed Shokeir, Mohamed Hamed, Alaa Samy, Gamal Karrouf

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yomna KhaterMedical Experimental Research Centre, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
Nashwa BarakatUrology and Nephrology Center, Mansoura University, Mansoura, 35516, Egypt.
Ahmed ShokeirUrology and Nephrology Center, Mansoura University, Mansoura, 35516, Egypt.
Mohamed HamedDepartment of Pathology, Faculty of Veterinary Medicine, University of Mansoura, Mansoura, 35516, Egypt.
Alaa SamyDepartment of Surgery, Anesthesiology, and Radiology, Faculty of Veterinary Medicine, University of Mansoura, Mansoura, 35516, Egypt.
Gamal KarroufDepartment of Surgery, Anesthesiology, and Radiology, Faculty of Veterinary Medicine, University of Mansoura, Mansoura, 35516, Egypt. gamalkarrouf@mans.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAlthough the relief of ureteral obstruction seems to be a radical treatment for obstructive uropathy (OU), progressive kidney damage is the result because of the associated increased apoptosis and fibrosis. Therefore, it is urgent to find a complementary renoprotective therapy against partially obstructed uropathy cascades. Thus, this study investigated the renoprotective effects of both losartan (LOS) and zinc oxide nanoparticles (ZnONPs) in partial unilateral ureteral obstruction (PUUO). MAIN

methodsIn controlled (n = 16) and shamed (n = 16) study, 64 healthy male Sprague-Dawley rats, both PUUO and right nephrectomy (RNX) were induced. The rats were equally allocated into four groups according to treatment protocol: (1) PUUO group (no treatment), (2) ZnONPs group, (3) LOS group and (4) ZnONPs/LOS group. Antioxidant status and gene expression were assessed in renal tissues. Moreover, histologic and immunohistochemical examinations were performed. KEY

findingsLOS and ZnONPs significantly mitigated the PUUO-induced renal injury, by significant (P < 0.0001) suppressing of oxidative stress (MDA and TOS), upregulating of antioxidant gene (SOD) and antiapoptotic gene (BCL2), and downregulating the expression of inflammatory cytokines (TNF-α, and IL6), apoptotic gene (Bax) and fibrotic marker (β-Catenin). The combination of both agents offered a more powerful renoprotective effect with additional significant upregulation of the antioxidant marker (TAC, P < 0.0001). SIGNIFICANCE: Both losartan and ZnONPs and specially their combination have synergistic action in protecting the kidney against PUUO-induced chronic renal cascades through improvement the renal function tests, amelioration of oxidative stress, inhibition of induced apoptosis and fibrosis with marked renal regeneration which highlights the possible application of these drugs as a complementary therapies for different chronic renal degenerative diseases.

Indexed as

LosartanNanoparticlesUreteral ObstructionZinc OxideAnimalsApoptosisbcl-2-Associated X ProteinDisease Models, AnimalDrug SynergismInterleukin-6MaleOxidative StressProto-Oncogene Proteins c-bcl-2RatsRats, Sprague-DawleySignal TransductionBax protein, ratbcl-2-Associated X ProteinBcl2 protein, ratIl6 protein, ratInterleukin-6LosartanProto-Oncogene Proteins c-bcl-2Tumor Necrosis Factor-alphaZinc OxideLosartanObstructive uropathyRenal tubulointerstitial damageZinc oxide nanoparticles

Identifiers

PMID39810058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.